Progressive Familial Intrahepatic Cholestasis — designated PFIC, encompassing a genetically heterogeneous group of autosomal recessive hepatocanalicular transport disorders unified by their shared clinical phenotype of severe chronic intrahepatic cholestasis with progressive hepatic fibrosis and their pathophysiological basis in mutations affecting the specialized transport proteins and tight junction components required for normal canalicular bile secretion — currently comprising at least six molecularly defined subtypes: PFIC1 (OMIM #211600, caused by biallelic loss-of-function mutations in ATP8B1 encoding FIC1, a type 4 P-type ATPase aminophospholipid flippase that maintains the asymmetric phospholipid composition of the canalicular membrane by translocating phosphatidylserine and phosphatidylethanolamine from the outer to the inner leaflet — mutations cause canalicular membrane destabilization and secondary impairment of the ABCB11/BSEP bile salt export pump through mechanisms not fully elucidated, producing low-GGT cholestasis with total serum bile acid elevation, severe pruritus, and extrahepatic manifestations including pancreatitis, diarrhea, and hearing loss that distinguish PFIC1 from other subtypes; hepatosteatosis and cirrhosis following liver transplantation is a recognized PFIC1-specific post-transplant complication attributed to systemic FIC1 deficiency in intestinal FIC1 expression); PFIC2 (OMIM #601847, caused by biallelic ABCB11 mutations encoding BSEP — the bile salt export pump that is the primary canalicular export protein responsible for secreting conjugated bile salts from hepatocytes into bile canaliculi, with complete BSEP deficiency producing the most severe PFIC phenotype, including the highest risk of hepatocellular carcinoma — HCC — across all PFIC subtypes, with HCC reported in PFIC2 patients in the first decade of life at an incidence substantially exceeding that of other pediatric cholestatic diseases, mandating dedicated HCC surveillance as a core management obligation; PFIC2 also features low-GGT cholestasis, very high serum bile acids, and extremely severe pruritus); PFIC3 (OMIM #602347, caused by biallelic ABCB4 mutations encoding MDR3 — the canalicular phosphatidylcholine (PC) flippase that exports PC into bile, where it forms protective mixed micelles with bile salts and phospholipids to prevent bile salt-mediated cytotoxicity to the bile duct epithelium; MDR3 deficiency causes biliary PC deficiency with high-GGT cholestasis — the elevated GGT that distinguishes PFIC3 from PFIC1 and PFIC2 — bile duct damage from detergent bile, progressive biliary cirrhosis, and a phenotype spectrum extending into adult patients with low-phospholipid-associated cholelithiasis [LPAC]); PFIC4 (caused by TJP2 mutations encoding tight junction protein 2, a scaffolding protein maintaining bile canalicular tight junction integrity); PFIC5 (caused by NR1H4 mutations encoding FXR, the farnesoid X receptor transcription factor that governs BSEP, SHP, and other bile acid metabolism gene expression — FXR loss functionally resembles BSEP deficiency and also carries HCC risk); and PFIC6 (caused by MYO5B mutations encoding myosin Vb, a motor protein required for canalicular transporter recycling — MYO5B mutations also cause MVID [microvillous inclusion disease] when the intestinal phenotype predominates); with the shared clinical features across PFIC subtypes being neonatal or infantile onset of cholestatic jaundice, progressive hepatic fibrosis advancing toward biliary cirrhosis and liver failure, and the debilitating symptom of intractable pruritus — particularly severe in PFIC1 and PFIC2 where high serum bile acid levels drive the bile acid-mediated itch signaling through cutaneous TMEM16A and TGR5 receptor pathways — that profoundly impairs sleep, behavior, and quality of life and is the primary driver of biliary diversion procedures; treated with ursodeoxycholic acid (UDCA) for cholestasis and pruritus management, partial biliary diversion (ileal exclusion or cholecystoappendicostomy to reduce the enterohepatic bile acid circulation), ileal bile acid transporter (IBAT) inhibitors including odevixibat (Bylvay, approved by FDA and EMA for PFIC) and maralixibat (Livmarli, approved for Alagille syndrome with PFIC use expanding), and liver transplantation as definitive treatment for liver failure or HCC in PFIC2; with a combined PFIC birth prevalence estimated at 1 in 50,000 to 1 in 100,000.
Progressive Familial Intrahepatic Cholestasis technology platforms — encompassing the neonatal and pediatric hepatology platforms where jaundiced neonates and infants with elevated serum bile acids, cholestatic liver function profiles, and severe pruritus enter the diagnostic pathway for PFIC subtype classification through serum GGT measurement (the critical first discriminator — low GGT directing toward PFIC1 or PFIC2 and high GGT toward PFIC3, drug-induced cholestasis, or biliary atresia), immunohistochemical staining of liver biopsy specimens for BSEP and MDR3 expression, and molecular genetic sequencing of ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, and MYO5B; the pruritus severity assessment platforms where validated patient-reported outcome tools including the visual analogue scale (VAS) and numerical rating scale (NRS) capture daily pruritus intensity across the day and night — the primary symptom burden and IBAT inhibitor efficacy measure tracked in digital care platforms and clinical trial platforms for odevixibat and maralixibat; the cholestasis biochemistry laboratory platforms where serum total bile acid quantification, ALT, GGT, total and direct bilirubin, albumin, and INR measurements are performed with the frequency required by cholestasis severity monitoring; the HCC surveillance platforms managing the AFP measurement and hepatic ultrasound intervals for PFIC2 and PFIC5 patients who carry substantially elevated HCC risk beginning in early childhood; the fat-soluble vitamin status monitoring platforms tracking vitamins A, D, E, and K levels that are chronically deficient in PFIC due to the combination of impaired bile acid-dependent micellar fat absorption and cholestatic intestinal fat malabsorption; the IBAT inhibitor prescribing and adherence monitoring platforms where odevixibat or maralixibat daily dosing, serum bile acid response, pruritus score response, and stool color (indirect evidence of biliary drainage improvement) are tracked with the precision required by the treatment response monitoring protocols; the biliary diversion surgical planning and post-operative monitoring platforms where partial biliary diversion — which interrupts the enterohepatic circulation by diverting bile from the terminal ileum — is evaluated, performed, and monitored for pruritus relief and cholestasis biochemistry improvement; and the liver transplant coordination platforms for the subset of PFIC patients who progress to liver failure or HCC — must maintain the availability and performance standards required by the diagnostic complexity of PFIC subtype classification, the HCC surveillance obligations of PFIC2 management, and the dynamic treatment response monitoring of IBAT inhibitor therapy. This guide explains why Progressive Familial Intrahepatic Cholestasis care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the bile acid surveillance, pruritus management, HCC prevention, fat-soluble vitamin correction, IBAT inhibitor monitoring, and liver transplant coordination obligations that define modern PFIC care.
Why PFIC Tech Platforms Require Specialized Monitoring Attention
Progressive Familial Intrahepatic Cholestasis management is defined by several uniquely complex care coordination challenges: the HCC surveillance imperative for PFIC2 and PFIC5 — because BSEP deficiency and FXR deficiency carry a markedly elevated HCC risk with tumors reported in patients under 5 years of age, the AFP and hepatic ultrasound surveillance platforms must maintain continuous availability during the intervals when surveillance monitoring is actively scheduled, and any platform failure that delays AFP result delivery or ultrasound scheduling in a PFIC2 patient creates an HCC surveillance gap that is oncologically unacceptable; the pruritus severity monitoring dynamic — because pruritus in PFIC1 and PFIC2 can be of such severity that it leads to self-injury, sleep deprivation, and behavioral disturbance in infants and toddlers, the real-time pruritus scoring platforms that capture parent-reported pruritus intensity are the primary quality-of-life monitoring and IBAT inhibitor treatment response measure, and their failure removes the primary signal used to titrate treatment and justify continued IBAT inhibitor prescribing; the fat-soluble vitamin deficiency cascade — PFIC patients have impaired micellar fat absorption due to cholestasis, placing them at risk of rickets (vitamin D), coagulopathy (vitamin K), hemolytic anemia (vitamin E), and xerophthalmia (vitamin A) — all preventable by supplementation monitored through the digital care platform, but catastrophic if missed; and the IBAT inhibitor treatment response monitoring complexity — odevixibat and maralixibat response monitoring requires simultaneous tracking of serum total bile acid reduction, pruritus score improvement, ALT normalization, and stool color observation, with the full multiparametric response assessment informing the decision to continue, escalate, or switch treatment.
Serum bile acid monitoring platforms are the primary cholestasis severity and IBAT inhibitor response measurement tool. Serum total bile acid quantification — elevated to 100–300 µmol/L or higher in untreated PFIC — is the primary biomarker of cholestatic severity, disease progression, and treatment response to odevixibat or maralixibat. Monitor bile acid quantification platforms at 1-minute intervals during laboratory hours.
HCC surveillance platforms for PFIC2 and PFIC5 are non-negotiable oncological monitoring obligations. AFP measurement and hepatic ultrasound for PFIC2 (and PFIC5) patients must be performed at prescribed intervals — typically every 3–6 months beginning from diagnosis — to detect HCC at a resectable stage. Monitor HCC surveillance platforms at 1-minute intervals.
Pruritus severity scoring platforms drive the primary quality-of-life and treatment efficacy signal. Daily or twice-daily pruritus NRS or VAS scores recorded by patients or caregivers in digital platforms constitute the primary patient-reported outcome tracked across PFIC management, biliary diversion evaluations, and IBAT inhibitor efficacy assessments. Monitor pruritus scoring platforms at 1-minute intervals during active reporting periods.
IBAT inhibitor prescribing and adherence platforms govern the logistics of the only approved pharmacotherapy for PFIC pruritus. Odevixibat and maralixibat require precise once-daily dosing with adherence monitoring, bile acid response tracking, and prescriber communication through digital platforms that cannot tolerate extended downtime during active titration periods. Monitor IBAT inhibitor management platforms at 1-minute intervals during clinical hours.
What to Monitor on a PFIC Care Tech Platform
Cholestasis Biochemistry and Liver Function Monitoring
Monitor serum total bile acid records (quantitative total bile acid measurement — primary PFIC disease severity biomarker and IBAT inhibitor response measure; elevated 50–300 µmol/L or higher in active PFIC; weekly measurement during IBAT inhibitor titration, monthly in stable disease; alert thresholds for treatment escalation), serum ALT records (alanine aminotransferase — marker of hepatocellular injury from bile acid-induced cytotoxicity; elevated in PFIC but pattern varies by subtype — extremely high ALT in PFIC2 from bile acid-mediated BSEP-deficient hepatocyte injury; moderate elevation in PFIC1 and PFIC3; ALT normalization is a secondary endpoint of IBAT inhibitor trials), GGT records (gamma-glutamyltransferase — the critical discriminating biomarker: low-normal GGT in PFIC1 and PFIC2 reflects absent canalicular bile acid transport without biliary epithelial injury; elevated GGT in PFIC3 reflects MDR3-deficient bile duct PC deficiency and detergent bile injury to bile duct epithelium; GGT is central to PFIC subtype classification at initial workup and monitoring during treatment), total and direct bilirubin records (cholestatic pattern — predominantly direct/conjugated bilirubin elevation; severity correlates with degree of canalicular dysfunction; jaundice management coordination), albumin and INR records (hepatic synthetic function markers — albumin decline and INR prolongation signal progressive hepatic decompensation toward liver failure; trigger for liver transplant evaluation escalation), alkaline phosphatase records (elevated in cholestasis — though age-specific normal ranges are critical in pediatric patients where bone alkaline phosphatase contributes substantially to total ALP), and serial liver function trend records (weekly during acute cholestasis and IBAT inhibitor titration; monthly in stable maintenance monitoring; graphical trending of bile acids, ALT, and GGT on the same longitudinal timeline) — at a 1-minute interval during laboratory hours.
HCC Surveillance (PFIC2 and PFIC5)
Monitor alpha-fetoprotein (AFP) records (serum AFP quantification — HCC tumor marker elevated in malignant hepatocellular transformation; AFP measurement every 3–6 months in PFIC2 and PFIC5 patients from diagnosis; alert threshold for AFP rise above age-specific reference range or change from baseline; AFP velocity calculation — rapid AFP rise is an oncological alert requiring urgent hepatic imaging), hepatic ultrasound surveillance records (hepatic ultrasound every 3–6 months in PFIC2 and PFIC5 patients — focal hepatic lesion detection; liver texture assessment for cirrhosis; portal vein diameter for portal hypertension; splenomegaly; AFP-suspicious lesion cross-sectional imaging referral workflow), cross-sectional hepatic imaging records (CT or MRI liver for ultrasound-detected or AFP-elevated suspicious lesions; multiphase contrast-enhanced liver MRI as gold standard for HCC characterization — arterial enhancement, washout appearance confirming LIRADS criteria), hepatic biopsy and histology records (BSEP immunostaining — absent or reduced canalicular BSEP staining in PFIC2 versus retained staining with reduced expression in milder BSEP variants; MDR3 immunostaining for PFIC3; hepatic fibrosis staging — F0–F4 Metavir or Ishak scoring; HCC pathological diagnosis and staging when biopsy performed), HCC treatment coordination records (liver-directed therapy — resection for localized HCC; transarterial chemoembolization; orthotopic liver transplantation as definitive therapy for HCC in PFIC2 — liver transplantation curative for both the PFIC liver disease and the HCC when performed within Milan criteria) — at a 1-minute interval during clinical and laboratory hours.
Pruritus Severity Assessment and Management
Monitor pruritus numerical rating scale (NRS) records (daily patient-reported or caregiver-reported pruritus intensity on 0–10 NRS — primary quality of life and treatment response endpoint; twice-daily scores during IBAT inhibitor titration [morning and evening] to capture diurnal pruritus pattern; weekly average NRS as the primary IBAT inhibitor efficacy metric in clinical trial protocols), scratching behavior records (objective scratching event counts from wrist-worn accelerometry devices used in PFIC clinical trials; parental observation logs of nighttime scratching, excoriation sites, and sleep disruption from pruritus), visual analogue scale (VAS) records (0–100 mm VAS for pruritus intensity as an alternative to NRS, used in some clinical trial protocols and PFIC registries), sleep disruption records (sleep quality impact from pruritus — nighttime awakening frequency, total sleep hours, need for antihistamines as pruritus relief; actigraphy data when available), pruritus management medication records (antihistamines — hydroxyzine, diphenhydramine for nighttime pruritus relief; rifampicin — CYP3A4 inducer increasing bile acid clearance; naltrexone — opioid antagonist for cholestatic pruritus; colestyramine — bile acid sequestrant; sertraline — SSRI with modest anti-pruritic effect in cholestasis), and pruritus treatment response correlation records (simultaneous trending of pruritus NRS and serum total bile acid — dose-response relationship between bile acid reduction and pruritus improvement) — at a 1-minute interval during active reporting periods.
IBAT Inhibitor Therapy Monitoring (Odevixibat and Maralixibat)
Monitor odevixibat prescribing records (daily dose in µg/kg — pediatric dosing 40 µg/kg/day for patients 6 months to 18 years for PFIC; maximum dose 120 µg/kg/day; once-daily morning dosing with food; dose escalation schedule; prescriber, pharmacy, and patient records synchronized in the digital platform), maralixibat prescribing records (daily dose in µg/kg — maralixibat dosing and titration schedule per approved prescribing information; dose escalation; pediatric and adult dosing weight-band calculation), IBAT inhibitor adherence records (daily dose confirmation — patient/caregiver app log; pharmacy dispensing interval; pill count reconciliation at clinic visit; electronic adherence monitoring device data when deployed), bile acid treatment response records (serum total bile acid measurement at baseline, week 4, week 12, and every 3 months during maintenance — treatment response defined as at least 50% reduction in serum total bile acid or normalization below 70 µmol/L; correlation of bile acid response with pruritus NRS improvement; complete responder versus partial responder versus non-responder categorization), stool color records (stool color chart documentation — darkening of stool color from acholic/pale (clay-colored) toward normal brown indicates improved biliary bile flow in response to IBAT inhibitor; digital photo capture stool color apps used in PFIC clinical trials), IBAT inhibitor adverse effect records (most common: diarrhea — from increased ileal bile acid presentation to the colon; abdominal pain; nausea; GI tolerability assessment leading to dose reduction or cessation), and IBAT inhibitor treatment decision records (continuation, dose escalation, switch between odevixibat and maralixibat, and biliary diversion referral if IBAT inhibitor response is inadequate) — at a 1-minute interval during clinical hours.
Fat-Soluble Vitamin Monitoring
Monitor vitamin A records (serum retinol quantification — deficiency defined as below 20 µg/dL; annual measurement in stable PFIC, every 6 months during active cholestasis; night blindness assessment; oral retinyl palmitate supplementation dose and adherence), vitamin D records (25-hydroxyvitamin D — 25(OH)D quantification; deficiency below 20 ng/mL; insufficiency 20–30 ng/mL; bone mineral density assessment via DXA when prolonged vitamin D deficiency; ergocalciferol or cholecalciferol supplementation dose), vitamin E records (alpha-tocopherol level; TPGS [tocopherol polyethylene glycol succinate] as the water-soluble vitamin E form with superior cholestatic absorption; deficiency can cause progressive peripheral neuropathy and hemolytic anemia in infants), vitamin K records (PT/INR as functional vitamin K status — impaired PT from vitamin K deficiency produces hemorrhagic risk; oral phytomenadione supplementation dose; IM administration for urgent correction; target INR below 1.3), combined fat-soluble vitamin panel records (quarterly vitamin panel during active cholestasis; annual panel in stable disease; supplementation adjustment records), and fat malabsorption nutritional support records (medium-chain triglyceride [MCT] formula supplementation — MCT absorption is bile acid-independent, providing a nutritional fat source in severe cholestatic fat malabsorption; enteral feeding support records when oral intake is inadequate) — at a 1-minute interval during laboratory and clinical hours.
PFIC Molecular Genetics and Subtype Classification
Monitor PFIC gene panel sequencing records (next-generation sequencing of ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, and MYO5B — biallelic variant identification with ACMG classification; subtype assignment based on genotype and GGT phenotype; deep sequencing for mosaic variants; deletion and duplication analysis for large rearrangements), liver biopsy immunohistochemistry records (BSEP immunostaining — canalicular BSEP expression pattern; absent expression confirming PFIC2 with null BSEP variants; retained partial expression in mild BSEP variants with non-null mutations; MDR3 immunostaining for PFIC3 confirmation; TJP2, FXR staining for PFIC4 and PFIC5 when available), PFIC registry enrollment records (enrollment in international PFIC registries — NAPPED consortium, ERN RARE-LIVER — enabling longitudinal natural history data capture and HCC surveillance verification), second-tier immunological records (anti-BSEP antibodies — BSEP antibody assay for PFIC2 patients post-liver transplantation; recurrent PFIC2 from anti-BSEP antibody-mediated allograft injury requiring immunosuppression intensification or rituximab), and PFIC variant classification update records (reclassification of variants of uncertain significance as additional functional data accrues) — at a 1-minute interval during laboratory hours.
Liver Transplant Coordination (PFIC)
Monitor PELD/MELD score records (liver transplant waitlist priority scoring for PFIC patients progressing to liver failure; monthly score update; exceptional case petition for HCC in PFIC2 meeting Milan criteria — standard PELD formulas may underestimate PFIC urgency in patients with preserved synthetic function despite advanced fibrosis and intractable pruritus), post-transplant complication records (PFIC1-specific post-transplant complication: hepatic steatosis, steatohepatitis, and cirrhosis in the allograft — attributed to intestinal FIC1 deficiency causing altered bile acid signaling and lipid metabolism; UDCA and dietary fat modification; biliary diversion of the transplanted liver in severe post-transplant PFIC1 steatosis; anti-BSEP antibody-mediated recurrent PFIC2 requiring immunosuppression adjustment or rituximab), biliary diversion surgical records (partial external biliary diversion or internal biliary diversion with cholecystoappendicostomy — surgical interruption of enterohepatic bile acid circulation as a liver-sparing intervention in PFIC1 and PFIC2 patients with adequate hepatic synthetic function; indication: inadequate IBAT inhibitor response; outcome monitoring: pruritus NRS, serum bile acids, biliary drainage volume and bile acid content, stoma care), and post-transplant immunosuppression and rejection monitoring records — at a 1-minute interval during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. PFIC management coordinates across neonatal medicine and pediatric gastroenterology (initial diagnosis and cholestasis management), molecular genetics (gene panel sequencing and PFIC subtype classification), hepatology (bile acid and liver function monitoring), oncology (HCC surveillance in PFIC2 and PFIC5), hepatobiliary surgery (biliary diversion procedures), liver transplantation surgery and hepatology (transplant coordination and post-transplant monitoring), dietetics and nutrition (fat-soluble vitamin supplementation and MCT formula support), ophthalmology (vitamin A deficiency screening), and clinical pharmacology (IBAT inhibitor prescribing and monitoring) — authentication failures block every team member required to execute the simultaneous HCC surveillance, pruritus monitoring, IBAT inhibitor management, and fat-soluble vitamin correction that PFIC management requires.
SSL Certificates
Monitor SSL certificate expiry across all cholestasis biochemistry laboratory platforms, HCC surveillance systems, pruritus scoring digital platforms, IBAT inhibitor prescribing and adherence management systems, liver transplant coordination portals, molecular genetics platforms, and fat-soluble vitamin monitoring systems. Certificate errors that disrupt the daily pruritus scoring apps used by families of PFIC patients at home create gaps in the patient-reported outcome data stream that are particularly damaging during clinical trial periods where pruritus NRS is the primary efficacy endpoint.
HIPAA and Ultra-Rare Genetic Disease Patient Privacy Considerations
Progressive Familial Intrahepatic Cholestasis technology platforms handle PHI for a patient population with combined birth prevalence of approximately 1 in 50,000–100,000 — rare enough that a PFIC diagnosis in a pediatric patient creates significant re-identification risk within regional care systems. Records include biallelic gene panel sequencing results across ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, and MYO5B (heritable mutations with implications for sibling carrier testing, 25% recurrence risk reproductive counseling, and extended family cascade testing), HCC surveillance results including AFP values and hepatic imaging findings (disclosing cancer surveillance status for pediatric patients with exceptionally elevated cancer risk), daily pruritus NRS and scratching behavior records (granular symptom severity documentation linked to pediatric patients), anti-BSEP antibody assay results post-transplant (disclosing organ transplant recipient status and post-transplant complication risk), IBAT inhibitor prescription records (disclosing odevixibat or maralixibat prescribing in a specific patient with a specific rare cholestatic liver disease), and fat-soluble vitamin deficiency records with supplementation histories.
The genetic nature of PFIC-causative mutations creates GINA protections for employment and insurance genetic discrimination in addition to HIPAA Privacy and Security Rule requirements. HCC surveillance platforms managing AFP results for pediatric PFIC2 patients represent an intersection of oncological surveillance, genetic disease, and pediatric PHI requiring particularly robust access controls and audit logging consistent with the HIPAA Security Rule.
Alerting Strategy for PFIC Tech Platforms
Immediate laboratory-hours alerting for HCC surveillance (PFIC2 and PFIC5): AFP measurement result delivery and hepatic ultrasound scheduling and reporting must not experience platform failures during active HCC surveillance intervals. A missed or delayed AFP or ultrasound in a PFIC2 patient represents an oncological monitoring failure.
Immediate laboratory-hours alerting for bile acid quantification and liver function platforms: Serum total bile acid, ALT, GGT, and synthetic function markers require immediate result delivery during active cholestasis management and IBAT inhibitor titration.
Immediate alerting for daily pruritus scoring platforms during active IBAT inhibitor titration: Gaps in pruritus NRS data during odevixibat or maralixibat titration remove the primary efficacy signal used to adjust dosing.
Immediate clinical-hours alerting for IBAT inhibitor prescribing, adherence, and response platforms: Odevixibat and maralixibat management requires continuous platform availability for prescriber communication, adherence monitoring, and treatment decision documentation.
Immediate clinical-hours alerting for liver transplant coordination: PELD/MELD calculation, donor notifications, and post-transplant complication monitoring platforms.
Sustained-failure alert (10–15 minutes): Fat-soluble vitamin monitoring, biliary diversion outcome tracking, genetic counseling, and PFIC registry enrollment platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms PFIC platform availability from the geographies where pediatric cholestatic liver disease programs, liver transplant centers, and rare metabolic liver disease genetics services serve PFIC patients across their management continuum.
Status Page for PFIC Care Team Communication
A real-time status page gives pediatric hepatologists monitoring bile acid trends and IBAT inhibitor responses, laboratory directors processing AFP and bile acid results for HCC surveillance, hepatobiliary surgeons managing biliary diversion outcomes, liver transplant coordinators tracking PELD scores and donor readiness, molecular geneticists classifying PFIC subtypes from gene panel results, clinical pharmacologists managing IBAT inhibitor titration, dietitians monitoring fat-soluble vitamin deficiency correction, and families logging daily pruritus scores in digital apps immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in PFIC HCC surveillance protocol documentation, IBAT inhibitor prescribing platform backup procedures, and liver transplant coordination on-call communication systems.
Vigilmon Setup for PFIC Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Serum total bile acid quantification | 1 min | Slack + PagerDuty (lab hours) | | ALT, GGT, and liver function panel | 1 min | Slack + PagerDuty (lab hours) | | AFP measurement (PFIC2 and PFIC5 HCC surveillance) | 1 min | Slack + PagerDuty (lab hours) | | Hepatic ultrasound scheduling and reporting | 1 min | Slack + PagerDuty (clinical hours) | | Cross-sectional liver imaging (CT/MRI) | 1 min | Slack + PagerDuty (radiology hours) | | Daily pruritus NRS/VAS scoring platform | 1 min | Slack + PagerDuty (reporting hours) | | Scratching behavior monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Odevixibat prescribing and adherence | 1 min | Slack + PagerDuty (clinical hours) | | Maralixibat prescribing and adherence | 1 min | Slack + PagerDuty (clinical hours) | | IBAT inhibitor treatment response (bile acid + NRS) | 1 min | Slack + PagerDuty (clinical hours) | | Stool color monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Vitamin A (retinol) level monitoring | 1 min | Slack + PagerDuty (lab hours) | | Vitamin D (25(OH)D) monitoring | 1 min | Slack + PagerDuty (lab hours) | | Vitamin E (alpha-tocopherol) monitoring | 1 min | Slack + PagerDuty (lab hours) | | Vitamin K / INR monitoring | 1 min | Slack + PagerDuty (lab hours) | | PFIC gene panel sequencing | 1 min | Slack + PagerDuty (lab hours) | | Liver biopsy immunohistochemistry (BSEP, MDR3) | 1 min | Slack + PagerDuty (lab hours) | | PELD/MELD and liver transplant waitlist | 1 min | Slack + PagerDuty (clinical hours) | | Post-transplant anti-BSEP antibody monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Biliary diversion outcome monitoring | 2 min | Slack (clinical hours) | | PFIC registry enrollment | 2 min | Slack (business hours) | | Genetic counseling and carrier testing | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure serum total bile acid quantification platforms with immediate laboratory-hours alerting
- Add AFP and hepatic ultrasound HCC surveillance platforms with immediate alerting for PFIC2 and PFIC5
- Configure ALT, GGT, and liver function platforms with immediate laboratory-hours alerting
- Add daily pruritus NRS/VAS scoring platforms with immediate alerting during active IBAT inhibitor titration
- Configure odevixibat and maralixibat prescribing and adherence platforms with immediate clinical-hours alerting
- Add IBAT inhibitor treatment response platforms combining bile acid and pruritus trend data
- Configure stool color monitoring platforms with immediate clinical-hours alerting
- Add fat-soluble vitamin panel platforms (A, D, E, K) with immediate laboratory-hours alerting
- Configure PFIC gene panel sequencing and liver biopsy immunohistochemistry platforms
- Add PELD/MELD and liver transplant coordination platforms with clinical-hours alerting
- Configure post-transplant anti-BSEP antibody monitoring platforms
- Add biliary diversion outcome monitoring with sustained-failure alerting
- Configure PFIC registry enrollment platforms with sustained-failure alerting
- Add genetic counseling and carrier testing platforms with business-hours alerting
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to HCC surveillance protocols and IBAT inhibitor prescribing system backup procedures
Conclusion
Progressive Familial Intrahepatic Cholestasis technology platforms are embedded in clinical decisions where AFP and hepatic ultrasound surveillance platform availability during the 6-month HCC surveillance interval for a 4-year-old PFIC2 patient — when the pediatric hepatologist is scheduling the routine AFP measurement and hepatic ultrasound mandated by the HCC surveillance protocol for a child with complete BSEP deficiency whose age and BSEP genotype place her at materially elevated risk of hepatocellular carcinoma that has been reported in PFIC2 patients in the first decade of life — cannot be disrupted by laboratory platform failures that delay the AFP result delivery while the clinical team is uncertain whether the prior ultrasound's small focal lesion has grown or resolved; where daily pruritus NRS scoring platform availability during odevixibat titration for a 2-year-old PFIC1 patient — whose parents are logging twice-daily pruritus scores in the digital patient-reported outcome app while the hepatology team uses the weekly average NRS to decide whether to escalate to the next dose tier at the 4-week reassessment — cannot be disrupted by pruritus scoring app failures that create a gap in the NRS data sequence at exactly the period when the treatment decision depends on complete 4-week pruritus trend data; and where serum total bile acid result delivery platform availability during the IBAT inhibitor response assessment for a 7-year-old PFIC3 patient — whose bile acid level at week 12 of odevixibat will determine whether the clinical team classifies her as a treatment responder and continues odevixibat or classifies her as a non-responder and proceeds to surgical biliary diversion evaluation — cannot be disrupted by laboratory result delivery failures that delay the bile acid measurement on which the most consequential therapeutic decision in this patient's management trajectory rests. A bile acid laboratory platform unavailable when HCC surveillance measurement must not be delayed in PFIC2, a pruritus scoring app interrupted when IBAT inhibitor titration requires continuous patient-reported outcome data, a liver transplant coordination system offline when a PFIC2 patient with rising AFP and a newly detected hepatic lesion is being evaluated for transplant within Milan criteria — these are not IT incidents. They are clinical disruptions in the management of a disorder where the consequences of cholestatic liver disease, bile acid-mediated hepatocellular injury, intractable pruritus, fat-soluble vitamin deficiency, and HCC risk accumulate continuously, making serum bile acid surveillance, pruritus monitoring, HCC vigilance, and IBAT inhibitor management platform continuous availability the operational foundation on which PFIC care coordination is built.
Uptime monitoring gives Progressive Familial Intrahepatic Cholestasis care tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric hepatology programs, liver transplant centers, and compliance auditors that platform operational reliability matches the continuous cholestasis biochemistry surveillance, HCC prevention monitoring, pruritus management, and IBAT inhibitor treatment tracking requirements that modern PFIC care demands.
Start monitoring your PFIC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #PFIC #progressive #familial #intrahepatic #cholestasis #ATP8B1 #FIC1 #ABCB11 #BSEP #ABCB4 #MDR3 #odevixibat #maralixibat #IBAT #bile #acid #pruritus #cholestasis #HCC #hepatocellular #carcinoma #AFP #liver #transplant #fat #soluble #vitamins #rare #genetic #pediatric #hepatology #HIPAA #healthtech #digitalhealth #uptime #sre